Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts

Objective Patients with rheumatoid arthritis (RA)-related autoantibodies have an increased mortality rate. Different autoantibodies are frequently co-occurring and it is unclear which autoantibodies associate with increased mortality. In addition, association with different causes of death is thus far unexplored. Both questions were addressed in three early RA populations. Methods 2331 patients with early RA included in Better Anti-Rheumatic Farmaco-Therapy cohort (BARFOT) (n=805), Norfolk Arthritis Register (NOAR) (n=678) and Leiden Early Arthritis Clinic cohort (EAC) (n=848) were studied. The presence of anticitrullinated protein antibodies (ACPA), rheumatoid factor (RF) and anticarbamylated protein (anti-CarP) antibodies was studied in relation to all-cause and cause-specific mortality, obtained from national death registers. Cox proportional hazards regression models (adjusted for age, sex, smoking and inclusion year) were constructed per cohort; data were combined in inverse-weighted meta-analyses. Results During 26 300 person-years of observation, 29% of BARFOT patients, 30% of NOAR and 18% of EAC patients died, corresponding to mortality rates of 24.9, 21.0 and 20.8 per 1000 person-years. The HR for all-cause mortality (95% CI) was 1.48 (1.22 to 1.79) for ACPA, 1.47 (1.22 to 1.78) for RF and 1.33 (1.11 to 1.60) for anti-CarP. When including all three antibodies in one model, RF was associated with all-cause mortality independent of other autoantibodies, HR 1.30 (1.04 to 1.63). When subsequently stratifying for death cause, ACPA positivity associated with increased cardiovascular death, HR 1.52 (1.04 to 2.21), and RF with increased neoplasm-related death, HR 1.64 (1.02 to 2.62), and respiratory disease-related death, HR 1.71 (1.01 to 2.88). Conclusions The presence of RF in patients with RA associates with an increased overall mortality rate. Cause-specific mortality rates differed between autoantibodies: ACPA associates with increased cardiovascular death and RF with death related to neoplasm and respiratory disease.

[1]  F. Berenbaum,et al.  IL2RA is associated with persistence of rheumatoid arthritis , 2015, Arthritis Research & Therapy.

[2]  A. Barton,et al.  Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. , 2015, JAMA.

[3]  J. Norris,et al.  Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis , 2015, The Journal of Rheumatology.

[4]  R. Toes,et al.  Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage , 2015, Arthritis Research & Therapy.

[5]  A. Barton,et al.  Association of HLA-DRB 1 HaplotypesWith Rheumatoid Arthritis Severity , Mortality , and Treatment Response , 2015 .

[6]  D. Symmons,et al.  Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts , 2014, Arthritis Research & Therapy.

[7]  N. Barbarroja,et al.  Anticyclic Citrullinated Protein Antibodies Are Implicated in the Development of Cardiovascular Disease in Rheumatoid Arthritis , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Akhmedov,et al.  Carbamylated low-density lipoprotein induces endothelial dysfunction. , 2014, European heart journal.

[9]  J. Drijfhout,et al.  Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. , 2014, Autoimmunity reviews.

[10]  L. Kuller,et al.  Determinants of Mortality Among Postmenopausal Women in the Women's Health Initiative Who Report Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[11]  D. van Schaardenburg,et al.  Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[12]  S. Ajeganova,et al.  Disease Factors in Early Rheumatoid Arthritis Are Associated with Differential Risks for Cardiovascular Events and Mortality Depending on Age at Onset: A 10-year Observational Cohort Study , 2013, The Journal of Rheumatology.

[13]  W. Robinson,et al.  Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. , 2013, Arthritis and rheumatism.

[14]  Banerjee Arnab,et al.  Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile? , 2013, Journal of cardiovascular disease research.

[15]  S. Humphries,et al.  Antibodies to citrullinated peptides and risk of coronary heart disease. , 2013, Atherosclerosis.

[16]  D. van Schaardenburg,et al.  Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. , 2013, Arthritis and rheumatism.

[17]  H. Steen,et al.  Carbamylation of Serum Albumin as a Risk Factor for Mortality in Patients with Kidney Failure , 2013, Science Translational Medicine.

[18]  Robert M. Plenge,et al.  Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis , 2011, Nature Genetics.

[19]  Sudhir V. Shah,et al.  Carbamylated low-density lipoprotein: nontraditional risk factor for cardiovascular events in patients with chronic kidney disease. , 2012, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[20]  S. Agewall,et al.  Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients , 2011, Scandinavian journal of rheumatology.

[21]  T. Huizinga,et al.  Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage , 2011, Proceedings of the National Academy of Sciences.

[22]  J. Morović-Vergles,et al.  Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis? , 2011, Rheumatology.

[23]  Rachel Knevel,et al.  Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? , 2011, Rheumatology.

[24]  S. le Cessie,et al.  Improved treatment strategies reduce the increased mortality risk in early RA patients. , 2010, Rheumatology.

[25]  D. M. van der Heijde,et al.  How to avoid phenotypic misclassification in using joint destruction as an outcome measure for rheumatoid arthritis? , 2010, Rheumatology.

[26]  A. Barton,et al.  Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients , 2010, Arthritis care & research.

[27]  S. Sánchez-Ramón,et al.  Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[28]  T. Therneau,et al.  Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. , 2008, The Journal of rheumatology.

[29]  A. Silman,et al.  Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis , 2008, Arthritis and rheumatism.

[30]  Y. Shoenfeld,et al.  Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[31]  E. Topol,et al.  Protein carbamylation links inflammation, smoking, uremia and atherogenesis , 2007, Nature Medicine.

[32]  E. Kulinskaya,et al.  Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. , 2006, Rheumatology.

[33]  J. Mustonen,et al.  The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[34]  L A Criswell,et al.  Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women’s Health Study , 2002, Annals of the rheumatic diseases.

[35]  A. Silman,et al.  Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. , 2002, Arthritis and rheumatism.

[36]  B. Svensson,et al.  Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy. , 2000, Rheumatology.

[37]  M. V. van Leeuwen,et al.  The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[38]  S. R. Dahlqvist,et al.  Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. , 1997, The Journal of rheumatology.

[39]  A. Silman,et al.  The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. , 1994, British journal of rheumatology.

[40]  H. Valdimarsson,et al.  Rheumatoid factor lsotypes and cancer prognosis , 1992, Cancer.

[41]  T. Delbanco,et al.  The rheumatoid factor: an analysis of clinical utility. , 1991, The American journal of medicine.

[42]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[43]  A. Giuliano,et al.  Rheumatoid factor in melanoma patients: Alterations of humoral tumor immunity in vitro , 1979, Cancer.

[44]  E. Saksela,et al.  Blocking Effect of Rheumatoid Factor on the In Vitro Cytotoxicity of Lymphoid Cells from Carcinoma Patients , 1976, Scandinavian journal of immunology.

[45]  E. Saksela,et al.  Rheumatoid factor as an indicator of serum blocking activity and tumour recurrences in bladder tumours. , 1976, European journal of cancer.

[46]  O. J. Björnsson,et al.  A population study of rheumatoid factor in Iceland. A 5-year follow-up of 50 women with rheumatoid factor (RF). , 1975, Annals of clinical research.

[47]  Gunnar B. Stickler,et al.  Prognosis , 1970 .